Search Results

This week in Terry's Corner you'll learn how model-based thinking helps you determine a drug’s mechanism Take the example Terry highlights: an agonist curve with a rightward shift and elevated baseline. Unlock “Mechanism of Action” now Only in Terry’s Corner   Why Terry’s Corner When early choices determine Terry’s Corner is designed to give you the edge. Subscribe to The Kenakin Brief today ➤

Terry's Corner – How Enzyme Inhibition Shapes Every Discovery Program Every molecule meets an enzyme This week’s Terry’s Corner reframes inhibition not as background theory—but as a design lens for smarter Kenakin — October 30, 12 PM EST Bring your toughest pharmacology questions and join Dr. Kenakin live. Each session shapes next month’s lessons—so your challenges guide the content. Kenakin Trusted insights across biotech, pharma, and academia 💎 $2,999/year — one conference cost =

This week, Terry’s Corner takes you beyond curve shapes into the kinetic and mechanistic realities that Terry's Corner - Demystifying Antagonism: The Key to Precision Drug Discovery Understanding the nuances Kenakin’s expert guidance provides a clear framework for distinguishing these mechanisms and avoiding Premium Members get 50%+ discount when they join Terry’s Corner. Keywords: GPCR, drug discovery, pharmacology, antagonism, competitive, non-competitive, Terry's Corner

Terry illustrates this with classic β-receptor partial agonists, showing how heart rate set-points under Terry’s Corner exists to fix that blind spot. Why Terry’s Corner Most pharmacology training freezes at equilibrium snapshots. Subscribe to The Kenakin Brief today ➤

Terry’s Corner: GPCR Pharmacology Insights That Prevent Real Drug Discovery Failures Discovery collapses Kenakin’s AMA made the central point unmistakable: GPCR systems constantly reshape ligand behavior through Premium Members get 67% discount when they join Terry’s Corner in 2025 Sharpen your interpretation skills

Terry's Corner – Orthosteric vs. This week in Terry's Corner, we focuse on the distinction between orthosteric and allosteric mechanisms overdose risk without sacrificing meaningful efficacy. 🎬 Plus New: Lesson Trailers   Curious about Terry Kenakin     💎 $2999/year — one conference cost = 12 months of expert training  Premium Dr.

Terry's Corner – Designing Drugs That Anticipate Physiological Pushback Most GPCR programs don’t fail This week’s Terry’s Corner  exposes the unseen physiological “opponents” your molecule faces—and how

Terry W. Moore, was most definitely a success.

While these signaling pathways are highly interconnected, they can also be regulated independently (Kenakin Kenakin, T. (2019). Biased receptor signaling in drug discovery.

In: Kenakin TP, editor A Pharmacology Primer (Sixth Edition). Kenakin TP. Kenakin TP. Kenakin T. The mass action equation in pharmacology. Kenakin T. Biased Receptor Signaling in Drug Discovery.

Kenakin and Hoare .

Kenakin and Hoare.

Kenakin and Hoare on '   Applying Pharmacology to Drug Discovery ' and ' Advanced Data Analysis for GPCR

Kenakin's upcoming course. We aim to make education accessible to all!

Kenakin, T. and A.

Kenakin's upcoming course. Our goal is to ensure that education is within reach for everyone!

Kenakin's upcoming course. We aim to make education accessible to all!

Kenakin will be back with two back-to-back classes.

extensive experimental datasets and in vivo validation which does not always align with in vitro evidence (Kenakin

kinases, emphasizing their role as hubs for increasing local effector concentrations near active GPCRs (Perry-Hauser

Ferry, G. Paul Greengard (1925–2019).